CLINICAL STUDY OVERVIEW

SCIENCE OVERVIEW

The collagen peptides used in Beauvyn have been evaluated in controlled clinical studies investigating their effects on skin appearance and joint function. Participants consumed 10g of hydrolysed collagen peptides daily, with outcomes measured using validated dermatological and musculoskeletal assessment methods.

Clinical Observations included:

  •  Improvements in Skin Hydration 
  •  Reductions in measured Skin Roughness
  •  Improvements in Skin Elasticity
  •  Improvements in Joint Comfort and Physical Function

WHY PEPTIDE SIZE MATTERS

Collagen peptides are broken down during digestion into smaller fragments known as peptides.


These peptides can be absorbed through the intestinal wall and transported in the bloodstream, where they may contribute to normal connective tissue processes.

Hydrolysed collagen peptides have been clinically studied in human trials** and shown to be efficiently absorbed into the bloodstream following ingestion. These studies demonstrate a significant increase in key collagen-building amino acids, including glycine, proline, and hydroxyproline—essential components for healthy skin, hair, nails, and joints.

Unlike standard collagen, hydrolysed peptides are broken down into smaller chains, allowing for enhanced bioavailability and improved uptake within the body. 

The ingredient Beauvyn uses is formulated using low molecular weight peptides (~2000 Daltons), aligning with clinical research to support optimal absorption and systemic availability.

COLLAGEN AND THE SKIN'S STRUCTURE

Skin is the largest organ in the body and contains several layers, including the epidermis and dermis. The dermis contains collagen and elastin, which contribute to the skin’s structure and elasticity.

As we age, natural collagen levels gradually decline, which can contribute to visible signs of ageing.

CLINICAL STUDY RESULTS ON SKIN  APPEARANCE

Participants taking collagen peptides showed improvements compared with placebo.

Based on the study summary, participants taking collagen peptides experienced:

  • Up to 30% improvement in measured skin hydration
  • More than 50% reduction in measured skin roughness
  • Over 15% improvement in skin elasticity

Skin Elasticity 

Clinical data shows that improvements in skin elasticity begin quickly after starting supplementation with the collagen peptide in Beauvyn, with measurable, statistically significant changes observed from the very early stages.

When compared to a placebo, the studied collagen peptide demonstrates a clear and noticeable advantage within just 4 weeks, highlighting how rapidly visible benefits can develop.

With continued use, these improvements become even more pronounced. Long-term supplementation with the collagen peptide in Beauvyn delivers a significant enhancement in skin elasticity versus placebo, exceeding a 15% improvement overall.

Importantly, benefits can begin from as early as week 1, with results building progressively over time, leading to optimal improvements by around week 8.

Skin Hydration

Clinical findings show that the collagen peptide in Beauvyn has a clear, positive impact on skin hydration, with early improvements visible after just one week of consistent use.

When compared to a placebo, the studied collagen peptide demonstrates a rapidly increasing benefit over time, with results becoming more pronounced by week 4.

Overall, supplementation with the collagen peptide in Beauvyn is associated with an increase in skin hydration of around 30% versus placebo. Notably, these improvements don’t just progress steadily they accelerate, highlighting a compounding effect with continued use.

Skin Roughness

Clinical data indicates that consistent supplementation with the collagen peptide in Beauvyn leads to a statistically significant improvement in skin smoothness from as early as week 1.

Compared to a placebo, the studied collagen peptide delivers a clear and visible benefit, with reductions in skin roughness exceeding 50%.

These improvements continue to build over time, with progressive smoothing effects observed through to week 12. The results highlight the consistent efficacy of the collagen peptide in Beauvyn, supporting ongoing, cumulative improvements in overall skin texture with regular use.

CLINICAL STUDY RESULTS ON JOINTS

In a randomised, double-blind, placebo-controlled trial, participants consuming hydrolysed collagen peptides daily were evaluated for joint comfort and physical function using validated assessment scales

Compared with placebo, participants taking collagen peptides experienced improvements in measured joint comfort and physical function.

IN CONCLUSION

Taken together, these clinical findings highlight the consistent, compounding benefits of the collagen peptide in Beauvyn across the key pillars of skin health and joint function. From improved hydration and enhanced elasticity to visibly smoother skin texture, results begin early and build progressively with continued use.

Rather than delivering short-term or isolated effects, the studied collagen peptide works over time to support meaningful, long-lasting improvements helping skin look healthier, feel stronger, and maintain its natural resilience.

 

 

These statements have not been evaluated by the Food Standards Agency or the European Food Safety Authority.
This product is a food supplement and is not intended to diagnose, treat, cure or prevent any disease.
Individual results may vary.
ClinicalTrials.gov Identifier: NCT05369780
ClinicalTrials.gov Identifier: NCT05235997
** PMCID: PMC6566347
 

 

 

Important Information

This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making changes to your diet, supplements, or treatment plan especially if you are pregnant, breastfeeding, taking medication, or have a medical condition.

Back to blog